Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:17:48.359Z.
Calculation as of: 2026-10-06T16:17:48.359Z.
Quote observation: 2026-10-06T16:15:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Mineralys Therapeutics, Inc.
Market Cap
$2.00B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.99B
Price/FCF Ratio
17.02
TTM Avg
21.03
3Y Avg
765.32
5Y Avg
894.72
Market Cap
$2.02B
Price/FCF Ratio
11.66
TTM Avg
15.26
3Y Avg
21.56
5Y Avg
21.56
Market Cap
$1.95B
Price/FCF Ratio
773.86
TTM Avg
497.87
3Y Avg
11182.67
5Y Avg
11182.67
Market Cap
$2.05B
Price/FCF Ratio
5.75
TTM Avg
22.88
3Y Avg
35.76
5Y Avg
35.76
Market Cap
$2.06B
Price/FCF Ratio
13.70
TTM Avg
9.83
3Y Avg
12.32
5Y Avg
13.49
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $2.00B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | 17.02 | 21.03 | 765.32 | 894.72 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 11.66 | 15.26 | 21.56 | 21.56 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 9.35 | 10.72 | 12.71 | 64.86 |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 773.86 | 497.87 | 11182.67 | 11182.67 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.05B | 5.75 | 22.88 | 35.76 | 35.76 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.06B | 13.70 | 9.83 | 12.32 | 13.49 |
| Alvotech (ALVO)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.93B | N/A | 53.35 | 53.35 | 53.35 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | N/A | 9.03 | 8.56 | 8.56 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
